Tilorone activates NK cells and cytotoxic lymphocytes that kill HLA-negative tumor cells

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Tilorone hydrochloride is a synthetic compound known for interferon induction, antiviral, and antitumor properties.
• Immune evasion by tumor cells presents a significant challenge in cancer therapy.
• Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are crucial for tumor surveillance and elimination.

Purpose of the Study:

• To investigate the capacity of tilorone hydrochloride to activate NK cells and cytotoxic T lymphocytes (CTLs).
• To analyze the mechanisms by which tilorone-activated lymphocytes recognize and kill immune-evasive tumor cells.
• To compare the characteristics of lymphocytes activated by tilorone with those activated by other immune stimulants like Tag7 and IL-2.

Main Methods:

• Treatment of human peripheral blood mononuclear cells (PBMCs) with tilorone hydrochloride, Tag7, and IL-2.
• Flow cytometry and functional assays to assess lymphocyte activation, phenotype, and cytotoxic activity.
• Analysis of the FasL-Fas interaction in tumor cell killing.

Main Results:

• Tilorone hydrochloride activates NK cells and specific subpopulations of CD4+ and CD8+ T lymphocytes.
• Activated lymphocytes effectively recognize and kill immune-evasive tumor cells through the FasL-Fas pathway.
• Lymphocytes activated by tilorone, Tag7, and IL-2 demonstrated similar target cell spectra, phenotypes, and cytotoxic mechanisms.
• Distinct early-stage immune response activation mechanisms were observed for each stimulant.

Conclusions:

• Tilorone hydrochloride is a potent activator of cytotoxic lymphocytes, including NK cells and CTLs, against immune-evasive tumors.
• The FasL-Fas interaction is a key mechanism for tilorone-mediated tumor cell killing.
• While different stimulants trigger distinct early immune responses, they converge on similar downstream lymphocyte activation pathways for tumor cell elimination.